Hypercalcemia

Hypercalcemia (serum calcium >10.5 mg/dL) affects ~1% of the population, with ~90% of cases caused by primary hyperparathyroidism (PHPT) or malignancy. [1] Severity classification: mild (<12 mg/dL), moderate (12–13.9 mg/dL), severe (≥14 mg/dL). [1] The classic mnemonic is "stones, bones, groans, thrones, and psychiatric overtones."

The following JAMA diagnostic algorithm outlines the PTH-based approach to evaluation:

• Onset and duration: acute (days–weeks, think malignancy) vs. chronic/incidental (months–years, think PHPT) [1]
• Symptom characterization: fatigue, weakness, anorexia, nausea/vomiting, constipation, polyuria, polydipsia, bone pain, abdominal pain [1]
• Neuropsychiatric: difficulty concentrating, confusion, lethargy, depression, anxiety [2]
• Medication/supplement review: thiazides, lithium, calcium supplements, vitamin D, vitamin A, teriparatide/abaloparatide, recent denosumab discontinuation [1-2]
• Dietary intake: excessive calcium or dairy, ketogenic diet [1]
• History of nephrolithiasis, fractures, pancreatitis [2]
• Known malignancy, weight loss, night sweats [2]
• Immobilization history [2]

• Calcium ≥14 mg/dL or rapidly rising (>1 mg/dL per 24 hours) [3]
• Altered mental status: confusion, somnolence, stupor, coma [1]
• Severe dehydration with hemodynamic instability
• ECG changes: short QT, prolonged PR, widened QRS, bradycardia, arrhythmias [1]
• New-onset seizures
• Acute kidney injury
• Signs of underlying malignancy: unexplained weight loss, palpable masses, pathologic fractures

Causative/contributing medications: [1-2]

• Thiazide diuretics — reduce renal calcium excretion
• Lithium — shifts PTH set point upward (PTH-dependent)
• Vitamin D supplements — especially at doses >4000 IU/day [1]
• Calcium supplements / antacids — milk-alkali syndrome
• Vitamin A excess
• Teriparatide / abaloparatide (synthetic PTH analogs)
• Denosumab discontinuation — rebound hypercalcemia [1]
• Immune checkpoint inhibitors, SGLT2 inhibitors — rare [1]

Contraindicated in hypercalcemia:

• Thiazides — worsen hypercalcemia
• Digitalis — enhanced sensitivity with hypercalcemia; increased arrhythmia risk [4]

• Discontinue excessive calcium and vitamin D supplementation [2]
• Avoid high-calcium foods acutely (dairy-heavy diets)
• Aggressive hydration is critical — encourage oral fluids in mild cases [1]
• Milk-alkali syndrome: excessive calcium carbonate antacid + dairy intake [2]
• Ketogenic diets have been associated with hypercalcemia (rare) [1]
• Long-term: moderate calcium intake (~1000 mg/day from diet) is generally acceptable in PHPT under monitoring

• GI: nausea, vomiting, constipation, abdominal pain, anorexia [1]
• Renal: polyuria, polydipsia, flank pain (nephrolithiasis), decreased urine output (AKI) [1]
• Neuro/Psych: fatigue, difficulty concentrating, lethargy, confusion, depression, anxiety [2]
• MSK: bone pain, muscle weakness, arthralgias [2]
• CV: palpitations, syncope [2]
• Constitutional: weight loss, night sweats, fevers (malignancy, granulomatous disease) [2]
• Pulmonary: cough, dyspnea (sarcoidosis, lung malignancy)

• Family history of hypercalcemia, hyperparathyroidism, MEN syndromes (MEN1, MEN2), or familial hypocalciuric hypercalcemia (FHH) [1-2]
• Family history of endocrine tumors (pituitary, pancreatic, adrenal) [5]
• Family history of nephrolithiasis or osteoporosis
• Social history: immobilization, supplement use, over-the-counter antacid use
• Occupational exposures relevant to granulomatous disease (TB, histoplasmosis, coccidioidomycosis) [2]

• Primary hyperparathyroidism: postmenopausal women, neck radiation, lithium use, MEN syndromes [2]
• Malignancy: squamous cell carcinomas (lung, head/neck), breast cancer, multiple myeloma, renal cell carcinoma, lymphoma [2-3]
• Granulomatous disease: sarcoidosis, TB, fungal infections [2]
• Immobilization — especially in Paget disease, adolescents, or patients with high bone turnover [2]
• Chronic kidney disease — tertiary hyperparathyroidism [2]
• Excessive supplementation: vitamin D, calcium, vitamin A [1]
• Endocrinopathies: thyrotoxicosis, adrenal insufficiency, pheochromocytoma [2]

Cannot-miss diagnoses: Hypercalcemia of malignancy (poor prognosis), parathyroid carcinoma, adrenal crisis, severe vitamin D intoxication. [1][7]

• Prior calcium levels (chronic vs. new-onset)
• History of nephrolithiasis, fractures, osteoporosis
• Known malignancy — type, stage, bone metastases
• Granulomatous disease (sarcoidosis, TB)
• Chronic kidney disease stage
• Prior neck surgery or radiation
• Pancreatitis episodes
• Endocrine disorders (thyroid disease, MEN syndromes, adrenal insufficiency)

• Vitals: tachycardia (dehydration), hypertension (if volume replete), hypotension (severe dehydration) [4]
• Volume status: dry mucous membranes, poor skin turgor, orthostatic changes — most patients with severe hypercalcemia are severely dehydrated [1]
• Neuro: hyporeflexia, proximal muscle weakness, altered mental status, lethargy [1]
• Neck: thyroid nodules, palpable parathyroid mass (rare, suggests carcinoma)
• Lymphadenopathy: sarcoidosis, lymphoma, metastatic disease [1]
• Abdomen: decreased bowel sounds (ileus from hypercalcemia), abdominal tenderness (pancreatitis)
• MSK: bone tenderness (metastases, fractures)
• Skin: band keratopathy (chronic hypercalcemia), calcinosis cutis
• Physical exam is often normal in mild hypercalcemia [1]

Initial workup:

• Serum calcium (repeat to confirm) + albumin (for corrected calcium) or ionized calcium [1]
• Intact PTH — the single most important initial test [1]
  • Elevated/normal PTH → PHPT (or FHH, lithium)
  • Suppressed PTH (<20 pg/mL) → malignancy, vitamin D–mediated, other [1]
• BMP: creatinine, BUN, electrolytes (phosphate often low in PTH/PTHrP-mediated causes) [1]
• Magnesium, phosphate

Directed second-tier labs (based on PTH result):

• If PTH suppressed: PTHrP, 25(OH)D, 1,25(OH)₂D, SPEP/UPEP, serum free light chains, TSH [1]
• If PTH elevated: 24-hour urine calcium and creatinine (to exclude FHH; Ca/Cr clearance ratio <0.01 suggests FHH) [2][6]
• CBC, LDH, alkaline phosphatase (bone turnover, malignancy)

Expected abnormalities:

• Low phosphate in PTH- or PTHrP-mediated hypercalcemia [1]
• Elevated phosphate in vitamin D–mediated or renal failure [1]
• Metabolic alkalosis in milk-alkali syndrome

• Chest X-ray / CT chest: lymphadenopathy (sarcoidosis, lymphoma), lung mass (squamous cell carcinoma) [1]
• Parathyroid imaging (not needed for diagnosis of PHPT, but for surgical planning): neck ultrasound, sestamibi-SPECT, or 4D-CT [2][6]
• Skeletal survey or PET/CT: if malignancy suspected (myeloma, metastatic disease)
• Renal ultrasound: nephrolithiasis, nephrocalcinosis
• DXA scan: for PHPT evaluation (not useful for myeloma bone disease) [8]
• Imaging is unnecessary for mild, asymptomatic, clearly PHPT-related hypercalcemia in the ED setting

• Corrected calcium formula: Adjusted Ca (mg/dL) = measured Ca + 0.8 × (4.0 − albumin g/dL) [3-4]
• Calcium-to-creatinine clearance ratio (CCCR): <0.01 suggests FHH [6]
• Genetic testing: CASR mutations (FHH), MEN1/MEN2 screening in young patients or familial cases [1-2]
• Bone marrow biopsy: if myeloma suspected
• ACE level: supportive (not diagnostic) for sarcoidosis
• Tissue biopsy: lymph node or mass biopsy for granulomatous disease or malignancy

Obtain ECG in all moderate-to-severe hypercalcemia: [1-2]

• Short QT interval — most characteristic finding [1][9]
• Prolonged PR interval [1]
• Widened QRS complex [1]
• Bradycardia [2]
• Osborn (J) waves — rare, severe cases
• Increased supraventricular and ventricular premature beats [9]
• Enhanced digitalis sensitivity — risk of digitalis toxicity [4]
• May unmask Brugada pattern in susceptible individuals [10]
• Severe hypercalcemia can progress to ventricular arrhythmias and cardiac arrest

Severity stratification: [1]

• Outpatient, chronic, mild, incidental → most likely PHPT [1]
• Inpatient, acute, symptomatic, severe → most likely malignancy [1]
• Rate of rise matters as much as absolute level — rapid increases are more dangerous [1][3]
• Complications: AKI, pancreatitis, nephrolithiasis, nephrocalcinosis, cardiac arrhythmias, coma [1]
• Hypercalcemia of malignancy carries poor prognosis — median survival often weeks to months [1]

Initial stabilization (severe/symptomatic hypercalcemia): [1][3][11]

• IV normal saline: bolus 1–2 L, then 200–500 mL/hr targeting urine output 100–150 mL/hr [3][11]
• Calcitonin (for rapid effect): 4–8 IU/kg SQ/IM q8–12h × 48–72 hours; lowers calcium by 1–2 mg/dL within hours; tachyphylaxis after 48–72 hours [1][11]
• Zoledronic acid 4 mg IV over 15 min (preferred) or pamidronate 60–90 mg IV over 2 hours — onset 48–72 hours; zoledronic acid normalizes calcium in 80–90% of patients with duration of 30–40 days [1][3]
  • [3][11]
• Loop diuretics (furosemide 20–40 mg): only after euvolemia achieved and only if volume overload risk [1][3]

Adjunctive/specific therapies

• Glucocorticoids (prednisone 60 mg/day × 10 days): first-line adjunct for vitamin D–mediated hypercalcemia (sarcoidosis, lymphoma, vitamin D intoxication) [1][3]
• Denosumab 120 mg SQ: for bisphosphonate-refractory hypercalcemia of malignancy or when bisphosphonates contraindicated (renal failure); can be given weekly × 4 weeks then monthly [3][11]
• Cinacalcet: for parathyroid carcinoma; 30 mg/day, titrate up to 90 mg QID [3]
• Dialysis with low-calcium dialysate: for severe CKD or life-threatening, refractory hypercalcemia [3]

Outpatient management (mild, asymptomatic PHPT)

• Parathyroidectomy if meeting surgical criteria (age <50, calcium >1 mg/dL above ULN, reduced BMD, renal involvement) [1]
• Observation with monitoring if criteria not met (especially age >50, calcium <1 mg/dL above ULN) [1]

• Admit (ICU or monitored bed): calcium ≥14 mg/dL, altered mental status, significant arrhythmias, severe dehydration, AKI, rapidly rising calcium [1][3]
• Admit (floor): moderate hypercalcemia (12–14 mg/dL) with symptoms, new diagnosis requiring urgent workup, inability to tolerate oral hydration
• Observation: moderate hypercalcemia with mild symptoms responding to initial hydration
• Discharge: mild, asymptomatic hypercalcemia (<12 mg/dL) with known chronic etiology (e.g., stable PHPT), adequate oral intake, reliable follow-up
• Specialist consultation triggers: endocrinology (PHPT, MEN syndromes), oncology (suspected/known malignancy), endocrine surgery (parathyroidectomy), nephrology (renal failure, dialysis consideration) [1]

• Follow-up timing: within 1–2 weeks for repeat calcium after ED discharge; sooner if symptomatic
• Return precautions — instruct patients to return for:
  • Persistent nausea/vomiting, inability to keep fluids down
  • Confusion, excessive drowsiness, or personality changes
  • Severe abdominal pain
  • Significant weakness or inability to ambulate
  • Decreased urine output
  • Palpitations or syncope
• Patient counseling:
  • Stay well hydrated (≥2–3 L fluids/day) [1]
  • Avoid thiazide diuretics, excessive calcium/vitamin D supplements
  • Avoid prolonged immobilization
• Expected course: mild PHPT has excellent prognosis with monitoring or surgery; hypercalcemia of malignancy carries a guarded prognosis [1]
• Ensure outpatient PTH and etiologic workup is completed if not done in ED

1. Hypercalcemia: A Review. — Walker MD, Shane E. The Journal of the American Medical Association. 2022.

2. Parathyroid Disorders. — Sell J, Ramirez S, Partin M. American Family Physician. 2022.

3. Cancer-Associated Hypercalcemia. — Guise TA, Wysolmerski JJ. The New England Journal of Medicine. 2022.

4. Management of Acute Hypercalcemia. — Bilezikian JP. The New England Journal of Medicine. 1992.

5. Neuroendocrine and Adrenal Tumors. — Updated 2026-04-21. National Comprehensive Cancer Network.

6. The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. — Wilhelm SM, Wang TS, Ruan DT, et al. JAMA Surgery. 2016.

7. Beyond Malignancy: Clinical Insights From Three Cases of Severe Hypercalcemia. — Ben Dori S, Kabaha N, Abu Husseine A, et al. Journal of Clinical Medicine. 2026.

8. Multiple Myeloma. — Updated 2026-01-09. National Comprehensive Cancer Network.

9. Reduction of Arrhythmias in Primary Hyperparathyroidism, by Parathyroidectomy, Evaluated With 24-H ECG Monitoring. — Pepe J, Cipriani C, Curione M, et al. European Journal of Endocrinology. 2018.

10. Opposite Calcium Disorders, Similar Electrical Risk: Reversible Cardiomyopathy Due to Hypocalcemia and Brugada Syndrome Unmasked by Hypercalcemia. — Megid TBC, Ubida C, de Melo Sousa Ferro AC, et al. Journal of Electrocardiology. 2026.

11. Treatment of Hypercalcemia of Malignancy in Adults: An Endocrine Society Clinical Practice Guideline. — El-Hajj Fuleihan G, Clines GA, Hu MI, et al. The Journal of Clinical Endocrinology and Metabolism. 2023.